The Cognitive and Cerebral Blood Flow Effects of Resveratrol

This study has been completed.

Sponsor:

Information provided by:

Northumbria University

ClinicalTrials.gov Identifier:

NCT01010009

First received: November 6, 2009

Last updated: May 17, 2012

Last verified: May 2012

History of Changes

Results First Received: June 26, 2010

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Crossover Assignment; Masking: Double Blind (Investigator, Outcomes Assessor); Primary Purpose: Basic Science
Condition:	Cognitive and Cerebral Blood Flow Effects of Resveratrol
Interventions:	Dietary Supplement: Trans- resveratrol Other: Placebo (silica)

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Resveratrol 250mg Then Resveratrol 500mg Then Placebo	No text entered.
Resveratrol 500mg Then Placebo Then Resveratrol 250mg	No text entered.
Placebo Then Resveratrol 250mg Then Resveratrol 500mg	No text entered.

Participant Flow: Overall Study

	Resveratrol 250mg Then Resveratrol 500mg Then Placebo	Resveratrol 500mg Then Placebo Then Resveratrol 250mg	Placebo Then Resveratrol 250mg Then Resveratrol 500mg
STARTED	8	8	8
COMPLETED	8	8	8
NOT COMPLETED	0	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Resveratrol 250mg Then Resveratrol 500mg Then Placebo	No text entered.
Resveratrol 500mg Then Placebo Then Resveratrol 250mg	No text entered.
Placebo Then Resveratrol 250mg Then Resveratrol 500mg	No text entered.
Total	Total of all reporting groups

Baseline Measures

	Resveratrol 250mg Then Resveratrol 500mg Then Placebo	Resveratrol 500mg Then Placebo Then Resveratrol 250mg	Placebo Then Resveratrol 250mg Then Resveratrol 500mg	Total
Number of Participants [units: participants]	8	8	8	24
Age [units: participants]
<=18 years	0	0	0	0
Between 18 and 65 years	8	8	8	24
>=65 years	0	0	0	0
Age [units: years] Mean ± Standard Deviation	19.2 ± 2.2	21.3 ± 1.8	20 ± 2	20 ± 2
Gender [units: participants]
Female	6	7	7	20
Male	2	1	1	4
Region of Enrollment [units: participants]
United Kingdom	8	8	8	24

Outcome Measures

Show All Outcome Measures

1. Primary:

Modulation of Levels of Total Haemoglobin [ Time Frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) ]

Show Outcome Measure 1

2. Primary:

Modulation of Deoxygenated Levels of Haemoglobin [ Time Frame: 0-81 mins (absorption period=1- 45 mins , post dose period 46- 81 mins) ]

Show Outcome Measure 2

3. Secondary:

Number of Participants With Significant Modulation of Cognitive Performance [ Time Frame: 46-81 mins post dose ]

Show Outcome Measure 3

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Emma Wightman
Organization: Northumbria university
phone: +44 (0) 191 2437253
e-mail: emma.l.wightman@unn.ac.uk

No publications provided

Responsible Party:	Emma Wightman, Northumbria University
ClinicalTrials.gov Identifier:	NCT01010009 History of Changes
Other Study ID Numbers:	22P2
Study First Received:	November 6, 2009
Results First Received:	June 26, 2010
Last Updated:	May 17, 2012
Health Authority:	United Kingdom: Research Ethics Committee

To Top